We are live on ! Find out more
NLSPW

NLS Pharmaceutics Warrant

Delisted

NLSPW was delisted on the 30th of October, 2025.

3 hedge funds and large institutions have $1.14K invested in NLS Pharmaceutics Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.8% less ownership

Funds ownership: 1.03%0.22% (-0.8%)

40% less funds holding

Funds holding: 53 (-2)

78% less capital invested

Capital invested by funds: $5.17K → $1.14K (-$4.03K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
2
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CS
1
Clear Street
New York
$744 -$4 -300 -0.5%
Citadel Advisors
2
Citadel Advisors
Florida
$237 -$7 -577 -3%
AC
3
Armistice Capital
New York
$161
WAM
4
Wolverine Asset Management
Illinois
-$3.19K -245,000 Closed
Hudson Bay Capital Management
5
Hudson Bay Capital Management
Connecticut
-$821 -71,356 Closed

NLSPW Hedge Fund Activity: Q1 2025 in Review

3 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q1 2025, worth a combined $1.14K — down 78% from $5.17K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NLSPW and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Wolverine Asset Management, exiting entirely with an estimated $3.19K sold.

  • 3 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q1 2025, down from 5 in Q4 2024.
  • Funds reported $1.14K of NLS Pharmaceutics Warrant stock for Q1 2025, down 78% quarter-over-quarter.
  • 0 funds opened new NLS Pharmaceutics Warrant positions in Q1 2025 and 2 closed out, a net change of -2 holders.
  • The largest NLS Pharmaceutics Warrant seller in Q1 2025 was Wolverine Asset Management, an estimated $3.19K sold.

Based on aggregated 13F filings for Q1 2025.